Long-term outcome of Guillain-Barré syndrome
Tóm tắt
To investigate long-term neurological residua after Guillain-Barré syndrome (GBS) and to evaluate the predictive value of respiratory insufficiency during the acute stage of the disease. Thirty-four patients with GBS including 5 patients with Miller-Fisher syndrome admitted to a university hospital between 1994 and 2002 underwent a neurological and electrophysiological follow-up examination 7–86 months after onset of GBS. Of the 34 patients, 5 patients had completely recovered, 11 patients demonstrated mild residual symptoms and/or signs, and 18 patients presented with functionally relevant neurological deficits predominantly in the lower extremity, although all patients could walk without assistance and none showed respiratory failure. Nerve conduction studies revealed abnormal findings in 30 patients. Autonomic function testing of the cardiovascular system showed a pathological blood pressure response to standing in 27 of 33 patients. No association was found between the course of the disease and sleep-disordered breathing at follow-up. Age at onset, need for mechanical ventilation, and duration of the plateau phase correlated with severity of neurological residua at follow-up. There was a high persistence of residual sensorimotor signs and symptoms after GBS in our cohort. In addition, abnormal blood pressure declines not associated with clinically over orthostatic dysregulation were detected in the majority of our patients at follow-up. This is in contrast to previous reports describing a gradual improvement of autonomic dysfunction after 2–18 months. A combined prognostic score based on patient age, duration of the plateau phase, and ventilatory failure in the acute stage of GBS might predict the long-term outcome.
Tài liệu tham khảo
Teitelbaum JS, Borel CO. Respiratory dysfunction in Guillain-Barre syndrome. clin Chest Med 1994;15(4):705–714.
Jiang GX, de Pedro-Cuesta J, Fredrikson S, Solders G. Guillain-Barre syndrome in south-west Stockholm, 1973–1991, 2. Clinical epidemiology. Ital J Neurol Sci 1997;18(1):49–53.
Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54(3): 620–625.
Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001;56(6):758–765.
Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology 2000;54(12):2311–2315.
Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol 2001;58(6):893–898.
Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64(1):74–77.
Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wijdicks EF. The morbidity of Guillain-Barre syndrome admitted to the intensive care unit. Neurology 2003;60(1):17–21.
Hughes RA, Raphel JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome Cochrane Database Syst Rev 2001(2):CD002063.
Pfeiffer G. [Dysautonomia in Guillain-Barre syndrome]. Nervenarzt 1999;70(2):136–148.
Cheng BC, Chang WN, Chang CS, et al. Guillain-Barre syndrome in southern Taiwan: clinical features, prognostic factors and therapeutic outcomes. Eur J Neurol 2003;10(6):655–662.
de Jager AE, Minderhoud JM. Residual signs in severe Guillain-Barre syndrome: analysis of 57 patients. J Neurol Sci 1991; 104(2):151–156.
Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barre syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63(4):494–500.
Ng YS, Lo YL, Lim PA. Characteristics and acute rehabilitation of Guillain-Barre syndrome in Singapore. Ann Acad Med Singapore 2004;33(3):314–319.
Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51(5):605–612.
Cheng Q, Jiang GX, Press R, et al. Clinical epidemiology of Guillain-Barre syndrome in adults in Sweden 1996–97: a prospective study. Eur J Neurol 2000;7(6):685–692.
Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM. Intensive management and treatment of severe Guillain-Barre syndrome. Crit Care Med 1993;21(3):433–446.
Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology 1999;53(3):598–604.
Nagashima T, Nishimoto Y, Hirata K, Yuki N. [Outcome after Guillain-Barre syndrome: comparison of motor function status and changes in social life]. Rinsho Shinkeigaku 2004;44(1):50–53.
Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2005;76(5):719–722.
Ropper AH, Wijdicks EFM, Truax BT. Guillan-Barré Syndrome. Philadelphia, PA: FA Davis Co, 1991:87–89.
de la Cour CD, Jakobsen J. Residual neuropathy in long-term population-based follow-up of Guillain-Barre syndrome. Neurology 2005;64(2):246–253.
Lyu RK, Tang LM, Hsu WC, Chen ST, Chang HS, Wu YR. A longitudinal cardiovascular autonomic function study in mild Guillain-Barre syndrome. Eur Neurol 2002;47(2):79–84.
Lyu RK, Tang LM, Hsu WC, Chen ST. Quantitative cardiovascular autonomic function study in Fisher syndrome. J Neurol Neurosurg Psychiatry 2002;73(3):333–335.
Singh NK, Jaiswal AK, Misra S, Srivastava PK. Assessment of autonomic dysfunction in Guillain-Barre syndrome and its prognostic implications. Acta Neurol Scand 1987;75(2):101–105.
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998;44(5):780–788.
Ziegler D, Laux G, Dannehl K, et al. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992;9(2):166–175.
American Sleep Disorders Association. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15(2):173–184.
Cheng Q, Wang DS, Jiang GX, et al. Prospective study of clinical epidemiology of Guillain-Barre syndrome in Harbin. China. J Neurol Sci 2003;215(1–2):63–69.
Vedeler CA, Wik E, Nyland H. The long-term prognosis of Guillain-Barre syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurol Scand 1997;95(5):298–302.
Dornonville de la Cour C, Andersen H, Stalberg E, Fuglsang-Frederiksen A, Jakobsen J. Electrophysiological signs of permanentaxonalloss in a follow-up study of patients with Guillain-Barre syndrome. Muscle Nerve 2005;31(1):70–77.
Bernsen RA, de Jager AE, Schmitz PI, van der Meche FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barre syndrome. Neurology 1999;53(2):409–410.
Bernsen RA, de Jager AE, van der Meche FG, Suurmeijer TP. How Guillain-Barre patients experience their functioning after 1 year. Acta Neurol Scand 2005;112(1):51–56.
Chowdhury D, Arora A. Axonal Guillain-Barre syndrome: a critical review. Acta Neurol Scand 2001;103(5):267–277.
Hughes RA, van der Meche FG. Corticosteroids for treating Guillain-Barre syndrome. Cochrane Database Syst Rev 2000(2): CD001446.
Lawn ND, Wijdicks EP. Fatal Guillain-Barre syndrome. Neurology 1999;52(3):635–638.
Melillo EM, Sethi JM, Mohsenin V. Guillain-Barre syndrome: rehabilitation outcome and recent developments. Yale J Biol Med 1998;71(5):383–389.
Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barre syndrome. A longitudinal study. Brain 1997;120(Pt 10):1885–1894.
Flachenecker P, Mullges W, Wermuth P, Hartung HP, Reiners K. Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guilain-Barre syndrome. Neurology 1996;47(1):102–108.
Annane D, Baudrie V, Blanc AS, Laude D, Raphael JC, Elghozi JL. Short-term variability of blood pressure and heart rate in Guillain-Barre syndrome without respiratory failure. Clin Sci (Lond) 1999; 96(6):613–621.
Flachenecker P, Lem K, Mullges W, Reiners K. Detection of serious bradyarrhythmias in Guillain-Barre syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum. Clin Auton Res 2000;10(4):185–191.
Hamilton RM, McKechnie PS, Macfarlane PW. Can cardiac vagal tone be estimated from the 10-second ECG? Int J Cardiol 2004; 95(1):109–115.
Pfeiffer G, Schiller B, Kruse J, Netzer J. Indicators of dysautonomia in severe Guillain-Barre syndrome. J Neurol 1999;246(11):1015–1022.
Raphael JC, Masson C, Morice V, et al. The Landry-Guillain-Barre syndrome. Study of prognostic factors in 223 cases]. Rev Neurol (Paris) 1986;142(6–7):613–624.
Bernsen RA, Jager AE, Schmitz PI, van der Meche FG. Long-term sensory deficit after Guillain-Barre syndrome. J Neurol 2001;248(6):483–486.
Cheng BC, Chang WN, Chang CS, et al. Predictive factors and long-term outcome of respiratory failure after Guillain-Barre syndrome. Am J Med Sci 2004;327(6):336–340.